(Total Views: 667)
Posted On: 08/02/2023 1:38:56 AM
Post# of 153822
"Merck still scouting for M&A deals, even after $10.8B takeover of Prometheus"
https://www.fiercepharma.com/pharma/merck-sti...prometheus
But buying out the San Diego immunology specialist has not satisfied Merck’s appetite for M&A, executives said during the company's second-quarter earnings call. “We continue to have a priority to do business development, so you should not necessarily expect a slowdown,” CEO Rob Davis said. “If and when assets that bring important scientific opportunities present themselves—where we see an alignment with strategy and where we can see value creation—we have the capacity and we will be willing to act on those."
https://www.fiercepharma.com/pharma/merck-sti...prometheus
But buying out the San Diego immunology specialist has not satisfied Merck’s appetite for M&A, executives said during the company's second-quarter earnings call. “We continue to have a priority to do business development, so you should not necessarily expect a slowdown,” CEO Rob Davis said. “If and when assets that bring important scientific opportunities present themselves—where we see an alignment with strategy and where we can see value creation—we have the capacity and we will be willing to act on those."
(12)
(0)
